Prime Medicine, Inc. Common Stock
PRMEPrime Medicine, Inc. (PRME) is a biotechnology company focused on developing gene editing therapies for genetic diseases. Leveraging its Prime Editing technology, the company aims to create precise, efficient, and versatile treatments to address a range of genetic conditions, with an emphasis on improving patient outcomes through innovative genomic editing solutions.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 12, 2019 | $0.80 | 2019-09-10 | 2019-09-11 |
| June 28, 2019 | $0.20 | 2019-06-14 | 2019-06-17 |
| December 31, 2018 | $0.21 | 2018-12-18 | 2018-12-19 |
| September 28, 2018 | $0.23 | 2018-09-14 | 2018-09-17 |
| June 29, 2018 | $0.15 | 2018-06-21 | 2018-06-22 |
Dividends Summary
- Prime Medicine, Inc. Common Stock has issued 15 dividend payments over the past 4 years
- The most recent dividend was paid 2279 days ago, on September 12, 2019
- The highest dividend payed out to investors during this period was $0.86 per share
- The average dividend paid during this period was $0.26 per share.
Company News
Prime Medicine published Phase 1/2 clinical data for PM359, an investigational gene therapy for chronic granulomatous disease, demonstrating safety and early clinical efficacy in two patients with promising results in neutrophil restoration and disease symptom improvement.
Prime Medicine reported Q2 2025 earnings with a net loss of $52.6 million, below analyst estimates. The company demonstrated clinical proof-of-concept for Prime Editing in chronic granulomatous disease and extended its cash runway into 2027 through strategic restructuring and funding.
Prime Medicine and Bristol Myers Squibb have entered a strategic research collaboration and license agreement worth over $3.5 billion. Prime Medicine will design optimized Prime Editor reagents for Bristol Myers Squibb's next-generation cell therapies, with Prime Medicine eligible for upfront and milestone payments.
We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.
